narmac - Had a quick look at Pfizer's product list just for fun. Looking alphabetically only there were 52 different drugs in the first 5 letters of the alphabet. I don't know how many of them ease symptoms of the 20 some odd areas that APB has a positive effect on but it's probably more than 1 and there is the rest of the alphabet to go. That short look didn't even get to Paxlovid which is expected to fetch $22 billion in sales this year alone. 

This is an example of one company only. For those on this board suggesting a planned delay in the entry of APB to the market, there sure seems to be good reason for that line of thinking. BP's are in the business of selling drugs not cures.

For a company that wants to sell a drug that may ease symptoms for many ailments APB could be their tick to multi billions of annual revenues. If RVX ever pulls this off, IMO Eversana has made the right choice.

tada